Patent ID: 9133524
Filing Date: 2015-09-15
Classification: C12N,C12Q,C12Y,G01N

Abstract:
1. A method of providing a prognosis for lung cancer in a human subject with lung cancer, the method comprising: (a) measuring the expression level of CSNK2A1P mRNA in a biological sample from the subject using a RT-PCR or quantitative PCR assay, wherein the assay comprises the use of a CSNK2A1P primer comprising the nucleotide sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO:10, and wherein the biological sample comprises lung tissue, and (b) providing a prognosis for lung cancer in the subject, wherein the prognosis for lung cancer is based on the expression level of CSNK2A1P mRNA in the sample, wherein a higher level of CSNK2A1P mRNA expression as compared to control lung tissue indicates a lower overall mortality rate, wherein a lower level of CSNK2A1P mRNA expression as compared to control lung tissue indicates a higher overall mortality rate, and wherein the CSNK2A1P mRNA encodes for a polypeptide comprising SEQ ID NO: 4.